Growth Hormone Secretion Following the Anaerobic Exercise
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01934270|
Recruitment Status : Recruiting
First Posted : September 4, 2013
Last Update Posted : March 22, 2018
Proper growth in children is a complex process regulated by a combination of genetic, nutritional, environmental, hormonal, and others. Growth hormone (GH) is the main hormone regulating the growth from childhood to adulthood. Despite great progress in the field, with the development of recombinant GH for the treatment of growth hormone deficiency (GHD), there is still no reliable method for testing GHD. Physical exertion is one of the significant physiologic stimuli for GH secretion, and it is reliable test for identification of GHD. It is not in use in the clinics because of its complexity. Recently GH secretion following short anaerobic exercise in young adults was tested and also demonstrated significant growth hormone secretion
In contrast to adult children's exercise is characterized by an anaerobic nature. There is no data about secretion of growth hormone in response to anaerobic exercise in children.
Purpose of the experiment:
The purpose of this study is to evaluate the secretion of growth hormone in response to anaerobic exercise in children.
|Condition or disease||Intervention/treatment||Phase|
|Short Stature||Other: Anaerobic Test||Not Applicable|
40 children (20 boys and 20 girls) aged 6-16 years, followed at the endocrinology unit for short stature clinics and need assessment of their growth hormone axis will be evaluate in parallel according to the currently accepted pharmacological GH testing as accepted and also following anaerobic physical test.
After explanation to the patient and his parent and obtaining an informed consent, the children will be instructed to pedal at maximum speed for 15 seconds x 10 sprints (1 minute of recovery between the sprints) against a resistance adjusted according to their body mass index.
The test will perform in similarity to GH provocative protocols by mean that they will be performed in the morning after a night's sleep and overnight fasting. The patients will be remained fasting during the test.
They will be asked not to exercise a day before the test. Thirty minutes before the test, Venflon will be inserted and the child will receive an explanation and rest until the beginning of the test. blood GH, IGF-1, cortisol will be taken at the beginning of exercise (time 0), at the end of exercise, after 30 minutes, 45 minutes and 60 minutes is customary according to criteria set pharmacological inventory growth hormone.
The test results will be compared to pharmacological testing of the child.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Growth Hormone Secretion Following the Anaerobic Exercise|
|Actual Study Start Date :||May 2014|
|Estimated Primary Completion Date :||December 30, 2018|
|Estimated Study Completion Date :||March 1, 2019|
|Experimental: Anaerobic Test||
Other: Anaerobic Test
To evaluate the secretion of growth hormone in response to anaerobic exercise in children.
- Growth Hormone Release [ Time Frame: GH will be measured at the beginning of exercise (time 0), and the change in GH level will be assessed at the end of exercise (30 seconds), after 10 minutes, 30 minutes and 60 minutes ]
- IGF-1 and Cortisol Release [ Time Frame: IGF-1, Cortisol will be taken at the beginning of exercise (time 0), at the end of exercise (30 seconds), after 10 minutes, 30 minutes and 60 minutes ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01934270
|Meir Medical Center||Recruiting|
|Kfar Saba, Israel|
|Contact: Dan Nemet, MD Dan.Nemet@clalit.org.il|
|Principal Investigator: Dan Nemet, MD|
|Principal Investigator:||Dan Nemet, MD||Meir Medical Center , Tel Aviv University|